MD, Department of Endocrinology, Diabetes, and Nutrition, Charité-University Medicine Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany.
J Clin Endocrinol Metab. 2013 Oct;98(10):4133-42. doi: 10.1210/jc.2013-1635. Epub 2013 Aug 21.
AIMS/HYPOTHESIS: The mechanisms underlying glucagon-induced satiety are incompletely understood. The glucagon-induced reduction in total ghrelin exerted at the hypothalamo-pituitary level might be responsible for this effect. Here we investigated glucagon-suppressive effects on circulating total and acyl-ghrelin, both in obesity and in type 1 diabetes mellitus (T1DM), with respect to the role of glucagon in appetite control. We further aimed to identify a possible mechanistic impact of changes in endogenous insulin.
In our prospective, double-blinded, placebo-controlled study, we investigated the endocrine and metabolic responses to intramuscular glucagon administration in 13 patients with T1DM (6 males, 7 females; body mass index [BMI] 24.8 ± 0.95 kg/m(2)), 11 obese participants (OP; 5 males, 6 females; BMI 34.4 ± 1.7 kg/m(2)), and 13 healthy lean participants (LP; 6 males, 7 females; BMI 21.7 ± 0.6 kg/m(2)).
As compared with placebo, glucagon significantly increased satiety index in T1DM and in LP (P < .001) but failed to induce satiety in OP (P = .152). Total ghrelin significantly decreased after glucagon administration in all study groups (P < .01). Similarly, acyl-ghrelin significantly decreased in LP (P < .01). However, acyl-ghrelin concentrations showed no change in OP (P = .248) and even increased substantially in T1DM (P < .01). Changes in acyl-ghrelin correlated positively with changes in nonesterified fatty acid concentrations in all groups (r = 0.31-0.43; P < .01).
CONCLUSIONS/INTERPRETATION: Glucagon-induced satiety was preserved in T1DM but not in obesity. This effect was unrelated to changes in total or acylated ghrelin and was independent of endogenous insulin release. In contrast to the insulin-independent glucagon-induced suppression of total ghrelin, glucagon- and/or insulin-induced modification of lipolysis may determine changes in acylated ghrelin.
目的/假设:胰高血糖素引起饱腹感的机制尚不完全清楚。在下丘脑-垂体水平上,胰高血糖素引起的总胃饥饿素减少可能是这种作用的原因。在这里,我们研究了胰高血糖素对肥胖和 1 型糖尿病(T1DM)患者循环总胃饥饿素和酰基胃饥饿素的抑制作用,以及胰高血糖素在食欲控制中的作用。我们还旨在确定内源性胰岛素变化的可能机制影响。
在我们的前瞻性、双盲、安慰剂对照研究中,我们研究了 13 名 T1DM 患者(6 名男性,7 名女性;体重指数[BMI]24.8 ± 0.95 kg/m²)、11 名肥胖参与者(OP;5 名男性,6 名女性;BMI 34.4 ± 1.7 kg/m²)和 13 名健康瘦参与者(LP;6 名男性,7 名女性;BMI 21.7 ± 0.6 kg/m²)肌肉内给予胰高血糖素后的内分泌和代谢反应。
与安慰剂相比,胰高血糖素显著增加了 T1DM 和 LP 中的饱腹感指数(P <.001),但未能诱导 OP 产生饱腹感(P =.152)。所有研究组给予胰高血糖素后总胃饥饿素水平均显著降低(P <.01)。同样,LP 中的酰基胃饥饿素也显著降低(P <.01)。然而,OP 中的酰基胃饥饿素浓度没有变化(P =.248),T1DM 中的酰基胃饥饿素浓度甚至显著增加(P <.01)。各组中酰基胃饥饿素的变化与非酯化脂肪酸浓度的变化呈正相关(r = 0.31-0.43;P <.01)。
结论/解释:T1DM 中胰高血糖素诱导的饱腹感得以保留,但肥胖中则不然。这种作用与总或酰基胃饥饿素的变化无关,且独立于内源性胰岛素释放。与胰岛素无关的胰高血糖素诱导的总胃饥饿素抑制作用相反,胰高血糖素和/或胰岛素诱导的脂肪分解修饰可能决定酰基胃饥饿素的变化。